Optimal treatment of intermediate risk prostate cancer remains unclear. National Comprehensive Cancer Network guidelines recommend active surveillance, prostatectomy or radiotherapy. Recent trials demonstrated no difference in prostate cancer specific mortality for men undergoing active surveillance for low risk prostate cancer compared to prostatectomy or radiotherapy.